Alterity Therapeutics Ltd (ATHE)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $37.42M
Last updated: Nov 17, 2026 at 10:57 AM ET
Earnings
Upcoming Estimates
Key Metrics
Technical Indicators Dashboard
As of Nov 16, 2026, the price is 34.4% below its 50-day moving average, and the 50-day average is below the 200-day average. The 14-day RSI is 31.9, in the neutral range between 30 and 70.
Moving Averages
MACD
ADX
Aroon & PSAR
Bollinger Bands
RSI (14-Day)
Momentum Oscillators
Volatility Measures
Volume Flow
Volume Metrics
Pivot Points
Advanced Oscillators
Financial Performance
Related GNG Research
No research available
Be the first to write about ATHE
News
ATHE Valuation
- P/B
- 1.2x
ATHE Profitability: Margins, ROIC and FCF
Alterity Therapeutics (ATHE) has an operating margin of -695.0% and a net margin of 0.0%.
- Operating margin
- -695.0%
- Net margin
- 0.0%
- ROE
- -55.0%
Alterity Therapeutics Competitors
The companies most similar to Alterity Therapeutics (ATHE) include Plus Therapeutics, OS Therapies and Grace Therapeutics.
Sector: Healthcare
ATHE Analyst Ratings
Alterity Therapeutics (ATHE) has a Buy consensus from 4 analysts: 4 Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell.
- Consensus
- Buy
- Analysts
- 4
- Strong Buy
- 1
- Buy
- 3
- Hold
- 0
- Sell
- 0
- Strong Sell
- 0
ATHE Bull Case vs Bear Case
Bear case
- ATHE's quarterly revenue changed -79.0% year over year.
Updated Sep 7, 2026. Built from end-of-day prices, company filings and consensus analyst estimates. Methodology
Frequently Asked Questions About ATHE
Does ATHE pay dividends?
Alterity Therapeutics Ltd (ATHE) does not currently pay a regular dividend.
What is ATHE's market cap?
Alterity Therapeutics Ltd (ATHE) has a market capitalization of $37.42M with a current stock price of $1.96.
How do analysts rate ATHE stock?
4 analysts cover Alterity Therapeutics Ltd (ATHE): 1 rate it Strong Buy, 3 Buy, 0 Hold, 0 Sell and 0 Strong Sell, a consensus of Buy.
ATHE pages: Overview, Financials
Get full access to GNG Research
Create a free account to access portfolio tracking, advanced tools, and more.